It Takes Two: GE Healthcare and SHINE Team Up

2017-12-18T18:11:06+00:00

November 9, 2015 - Today, SHINE and GE Healthcare announced they have successfully obtained pharmaceutical-grade Tc‑99m from GE Healthcare’s DRYTEC™ Tc-99m (Kit for the Preparation of Sodium Pertechnetate Technetium Tc99m Injection), using Mo-99 produced by SHINE’s innovative process.

It Takes Two: GE Healthcare and SHINE Team Up 2017-12-18T18:11:06+00:00

SHINE Achieves Major Milestone on Path to Construction Permit Approval

2017-07-31T18:53:28+00:00

October 26, 2015 - SHINE Medical Technologies, Inc., a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical tracers and cancer treatment elements, announced today that the staff of its primary regulator, the Nuclear Regulatory Commission (NRC), has completed their safety and environmental reviews and recommends approval of a Construction Permit for the SHINE facility.

SHINE Achieves Major Milestone on Path to Construction Permit Approval 2017-07-31T18:53:28+00:00

Additional $2M DOE/NNSA Award Accelerates SHINE Project

2017-08-01T08:41:23+00:00

October 25, 2015 - SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based medical isotope company, announced today that it has been awarded $1 million from the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) as part of a $2 million cooperative agreement.

Additional $2M DOE/NNSA Award Accelerates SHINE Project 2017-08-01T08:41:23+00:00

SHINE Signs License Agreement for SRNL Innovation

2017-07-31T19:30:02+00:00

October 14, 2015 - Savannah River Nuclear Solutions, LLC (SRNS), the management and operating contractor for the U.S. Department of Energy’s Savannah River National Laboratory (SRNL), has granted SHINE Medical Technologies, Inc. (SHINE) an exclusive license on SRNL’s patented hydrogen isotope separation process for use in medical isotope production.

SHINE Signs License Agreement for SRNL Innovation 2017-07-31T19:30:02+00:00

Todd Asmuth Joins SHINE Team

2017-08-01T08:41:59+00:00

October 1, 2015 - SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that Todd Asmuth will join the company as President, reporting to the CEO and focusing on investor and customer relations. The appointment comes as the company prepares to bring its first product to market, molybdenum-99 (moly-99).

Todd Asmuth Joins SHINE Team 2017-08-01T08:41:59+00:00

NSF Award Accelerates SHINE Efforts to Become a Major Iodine-131 Producer

2017-08-01T08:42:41+00:00

June 30, 2015 - SHINE Medical Technologies, a Wisconsin-based medical isotope company, announced today that it has been awarded $150,000 from the National Science Foundation for Phase I of an SBIR (Small Business Innovation Research) Grant. This grant will fast-track SHINE’s ongoing development of iodine-131 extraction and purification processes, which SHINE may decide to pursue at its medical isotope production facility.

NSF Award Accelerates SHINE Efforts to Become a Major Iodine-131 Producer 2017-08-01T08:42:41+00:00

Argonne Demo of SHINE Process Produces Commercial-Grade Medical Isotopes

2017-08-01T08:55:46+00:00

June 15, 2015 - Argonne National Laboratory (Argonne) and SHINE Medical Technologies, Inc. announced today that Argonne successfully demonstrated the production, separation and purification of molybdenum-99 (Mo-99) from SHINE’s innovative liquid target. The resulting Mo-99 product purity was equivalent to the Mo-99 used in the supply chain today. The demonstration—known as Mini-SHINE— uses the same process flows that will be used in the SHINE manufacturing facility and further validates SHINE’s technical approach.

Argonne Demo of SHINE Process Produces Commercial-Grade Medical Isotopes 2017-08-01T08:55:46+00:00

NRC Issues Draft EIS for SHINE Facility

2017-09-18T13:32:06+00:00

May 21, 2015 - SHINE Medical Technologies, a Wisconsin-based company dedicated to being the world leader in safe, clean, affordable production of medical isotopes, announced today that the Company’s primary regulator, the Nuclear Regulatory Commission (NRC), has released for public review and comment the draft Environmental Impact Statement (EIS) for the SHINE medical isotope production facility in Janesville, WI.

NRC Issues Draft EIS for SHINE Facility 2017-09-18T13:32:06+00:00

SHINE and Phoenix Sign Development and Supply Agreement

2017-08-01T08:46:06+00:00

January 7, 2015 - SHINE Medical Technologies and Phoenix Nuclear Labs (PNL) announced today that they have entered into an exclusive, long-term development and supply agreement. This agreement builds on an existing partnership and lays the foundation for a commercial relationship going forward.

SHINE and Phoenix Sign Development and Supply Agreement 2017-08-01T08:46:06+00:00

Lantheus and SHINE Announce Mo-99 Supply Agreement

2017-08-01T08:46:28+00:00

November 5, 2014 - Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents, and SHINE Medical Technologies, Inc., a Wisconsin-based company dedicated to being the world leader in safe, clean, affordable production of medical isotopes, today announced that the companies have entered into a strategic agreement for the future supply of molybdenum-99 (Mo-99).

Lantheus and SHINE Announce Mo-99 Supply Agreement 2017-08-01T08:46:28+00:00